| Lifetime Psychiatry Llc | |
|
5700 Mexico Rd Ste 8 Saint Peters MO 63376-1667 | |
| (636) 477-6464 | |
| (636) 410-9291 |
| Full Name | Lifetime Psychiatry Llc |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 5700 Mexico Rd Ste 8, Saint Peters, Missouri |
| Authorized Official Name and Position | Karrie Copeland (PRACTICE MANAGER) |
| Authorized Official Contact | 6364776464 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Lifetime Psychiatry Llc 5700 Mexico Rd Ste 8 Saint Peters MO 63376-1667 Ph: (636) 477-6464 | Lifetime Psychiatry Llc 5700 Mexico Rd Ste 8 Saint Peters MO 63376-1667 Ph: (636) 477-6464 |
| NPI Number | 1225613557 |
|---|---|
| Provider Enumeration Date | 03/17/2021 |
| Last Update Date | 03/17/2021 |
| Certification Date | 03/17/2021 |
| Medicare PECOS PAC ID | 5496150799 |
|---|---|
| Medicare Enrollment ID | O20210825001437 |
News Archive
Peri-implantitis, a condition where tissue and bone around dental implants becomes infected, besets roughly one-quarter of dental implant patients, and currently there's no reliable way to assess how patients will respond to treatment of this condition.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
People around the world dramatically changed their shopping behaviors at the start of the COVID-19 pandemic.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225613557 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | (* (Not Available)) | Primary |
| Provider Name | Nan H Roberts |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528172103 PECOS PAC ID: 2567519424 Enrollment ID: I20090409000563 |
News Archive
Peri-implantitis, a condition where tissue and bone around dental implants becomes infected, besets roughly one-quarter of dental implant patients, and currently there's no reliable way to assess how patients will respond to treatment of this condition.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
People around the world dramatically changed their shopping behaviors at the start of the COVID-19 pandemic.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
› Verified 6 days ago
| Provider Name | Stacia S Woods |
|---|---|
| Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
| Provider Identifiers | NPI Number: 1780167478 PECOS PAC ID: 8123446036 Enrollment ID: I20200910000828 |
News Archive
Peri-implantitis, a condition where tissue and bone around dental implants becomes infected, besets roughly one-quarter of dental implant patients, and currently there's no reliable way to assess how patients will respond to treatment of this condition.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
People around the world dramatically changed their shopping behaviors at the start of the COVID-19 pandemic.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
› Verified 6 days ago
| Provider Name | Jaime Renee Hamilton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992467625 PECOS PAC ID: 8123417417 Enrollment ID: I20211108000283 |
News Archive
Peri-implantitis, a condition where tissue and bone around dental implants becomes infected, besets roughly one-quarter of dental implant patients, and currently there's no reliable way to assess how patients will respond to treatment of this condition.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
People around the world dramatically changed their shopping behaviors at the start of the COVID-19 pandemic.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
› Verified 6 days ago
| Provider Name | Beth Marilyn Glenn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003559808 PECOS PAC ID: 4082093083 Enrollment ID: I20220622001835 |
News Archive
Peri-implantitis, a condition where tissue and bone around dental implants becomes infected, besets roughly one-quarter of dental implant patients, and currently there's no reliable way to assess how patients will respond to treatment of this condition.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
People around the world dramatically changed their shopping behaviors at the start of the COVID-19 pandemic.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
› Verified 6 days ago
| Provider Name | Candace Danielle Benford |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679205140 PECOS PAC ID: 9436535895 Enrollment ID: I20221007002695 |
News Archive
Peri-implantitis, a condition where tissue and bone around dental implants becomes infected, besets roughly one-quarter of dental implant patients, and currently there's no reliable way to assess how patients will respond to treatment of this condition.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
People around the world dramatically changed their shopping behaviors at the start of the COVID-19 pandemic.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
› Verified 6 days ago
| Provider Name | Erika Milbner Gotway |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902505795 PECOS PAC ID: 4789043670 Enrollment ID: I20230711000511 |
News Archive
Peri-implantitis, a condition where tissue and bone around dental implants becomes infected, besets roughly one-quarter of dental implant patients, and currently there's no reliable way to assess how patients will respond to treatment of this condition.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
People around the world dramatically changed their shopping behaviors at the start of the COVID-19 pandemic.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
› Verified 6 days ago
News Archive
Peri-implantitis, a condition where tissue and bone around dental implants becomes infected, besets roughly one-quarter of dental implant patients, and currently there's no reliable way to assess how patients will respond to treatment of this condition.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
People around the world dramatically changed their shopping behaviors at the start of the COVID-19 pandemic.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
› Verified 6 days ago
Thin Line Counseling Services, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 114 Siena Dr, Saint Peters, MO 63376 Phone: 314-297-0331 | |
Integrative Psychiatric Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1 Mid Rivers Mall Dr Ste 360, Saint Peters, MO 63376 Phone: 636-386-4792 | |
The Nest Holistics Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1600 Heritage Lndg, Saint Peters, MO 63303 Phone: 636-486-7626 | |
Serenity Health Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 4905 Mexico Rd Ste 400, Saint Peters, MO 63376 Phone: 314-590-3721 Fax: 314-214-7380 | |
Life Way Counseling Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4650 Mexico Rd, Saint Peters, MO 63376 Phone: 636-498-9326 | |
Terry Diane Miller Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 255 Spencer Rd, Suite 201, Saint Peters, MO 63376 Phone: 636-939-2550 Fax: 636-939-2551 | |
Recovery Transitions, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4650 Mexico Rd, Saint Peters, MO 63376 Phone: 314-945-6811 |